Article Dans Une Revue Molecular Therapy - Methods and Clinical Development Année : 2024

Synergy between Lactobacillus murinus and anti-PcrV antibody delivered in the airways to boost protection against Pseudomonas aeruginosa

Résumé

Therapeutic antibodies (Ab) have revolutionized the management of multiple illnesses including respiratory tract infections (RTIs). However, anti-infectious Ab displayed several limitations including antigen restrictiveness, narrowed therapeutic windows and limited dose in the vicinity of the target when delivered by parenteral routes. Strategies enhancing further Ab-dependent containment of infection is currently needed. Here we showed that a combination of inhaled anti-infectious Ab and probiotics is an efficient formulation to protect against lung infection. Using a mouse model of Pseudomonas aeruginosa -induced pneumonia, we demonstrated a synergistic effect reducing both bacterial burden and pro-inflammatory response affording protection against primary and secondary infections. This is the first study showing that the local combination of anti-infective Ab and probiotics, subverts suboptimal potency of Ab monotherapy and provides local protection against respiratory pathogen.

Domaines

Médicaments
Fichier principal
Vignette du fichier
Secher_et_al_MTM-D-23-00371R2_Revised_manuscript.pdf (222.67 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04834283 , version 1 (07-01-2025)

Identifiants

Citer

Thomas Secher, Mélanie Cortes, Chloé Boisseau, Marie-Thérèse Barba Goudiaby, Aubin Pitiot, et al.. Synergy between Lactobacillus murinus and anti-PcrV antibody delivered in the airways to boost protection against Pseudomonas aeruginosa. Molecular Therapy - Methods and Clinical Development, 2024, 32 (4), pp.101330. ⟨10.1016/j.omtm.2024.101330⟩. ⟨hal-04834283⟩
20 Consultations
0 Téléchargements

Altmetric

Partager

More